FrancophonIA/ELRC3.0 huggingface dataset:
English: Lung function, asthma symptom score, ACQ-6 and AQLQ(S)+12 were also assessed in Trial 3 and showed results similar to those in Trials 1 and 2.
Croatian: U Ispitivanju 3 također su se ocjenjivali plućna funkcija, rezultat za simptome astme te rezultati upitnika ACQ-6 i AQLQ(S)+12, a nalazi su bili slični onima iz Ispitivanja 1 i 2.
English: Step 6 - Pull off the cap
Croatian: 6. korak - Skinite zatvarač
English: Patients had a history of 2 or more asthma exacerbations requiring oral or systemic corticosteroid treatment (mean of 3) in the past 12 months, ACQ-6 score of 1.5 or more at screening, and reduced lung function at baseline (mean predicted pre-bronchodilator forced expiratory volume in 1 second [FEV1] of 57.5%), despite regular treatment with high-dose inhaled corticosteroid (ICS) (Trial 1) or with medium or high-dose ICS (Trial 2) and a long-acting β-agonist (LABA); at least one additional controller was administered to 51% and 41% of these patients, respectively.
Croatian: Asthma Control Questionnaire-6, ACQ-6) pri probiru te smanjenu plućnu funkciju na početku ispitivanja (srednja vrijednost procijenjenog forsiranog izdisajnog volumena u 1 sekundi [FEV1] prije primjene bronhodilatatora bila je 57,5%) unatoč redovitom liječenju visokim dozama inhalacijskih kortikosteroida (IKS) (Ispitivanje 1) odnosno umjerenim do visokim dozama IKS-a (Ispitivanje 2) te dugodjelujućim β-agonistom (engl. long-acting β-agonist, LABA); primijenjen je najmanje jedan dodatni lijek za terapiju održavanja u 51% bolesnika u Ispitivanju 1 i 41% u Ispitivanju 2.
English: Difference (95% CI) AQLQ(S)+12
Croatian: AQLQ(S)+12
English: Do not fan or blow on the cleaned area.
Croatian: Nemojte sušiti očišćeno područje vrućim zrakom ni puhanjem.
English: Trial 4
Croatian: Ispitivanje 4
English: Maintenance of the reduction in daily OCS dose was also observed over the extension trial in patients enrolled from Trial 3 (Figure 1).
Croatian: Kod bolesnika uključenih iz Ispitivanja 3 je tijekom cijelog produžetka ispitivanja opaženo i održano smanjenje dnevne doze OKS-a (Slika 1).
English: Each Fasenra pre-filled syringe contains 1 dose of Fasenra that is for one-time use only.
Croatian: Jedna napunjena štrcaljka s lijekom Fasenra sadrži 1 dozu lijeka Fasenra namijenjenu samo za jednokratnu primjenu.
English: Similar improvement in favour of Fasenra was observed for the Asthma Control Questionnaire-6 (ACQ-6) and Standardised Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) (Table 3).
Croatian: Standardised Asthma Quality of Life Questionnaire for 12 Years and Older, AQLQ(S)+12) (Tablica 3).
English: Do not use Fasenra if liquid is cloudy, discoloured, or if it contains large particles or foreign particulate matter.
Croatian: Nemojte primijeniti lijek Fasenra ako je otopina mutna, ako je promijenila boju ili ako sadrži velike ili strane čestice.
English: Mean baseline (SD) Change from baseline (SD)
Croatian: Srednja početna vrijednost (SD) Promjena od početne vrijednosti (SD)
English: Nervous system disorders
Croatian: Poremećaji živčanog sustava glavobolja često
English: Drug-Drug interaction
Croatian: Associated Drug Co.
English: Table 5 summarizes the study results for Trial 3.
Croatian: Rezultati Ispitivanja 3 sažeto su prikazani u Tablici 5.
English: In both trials, patients receiving Fasenra experienced significant reductions in annual exacerbation rates compared to placebo in patients with blood eosinophils ≥300 cells/μL.
Croatian: U oba ispitivanja, bolesnici koji su imali razinu eozinofila u krvi ≥ 300 stanica/μl i koji su primali lijek Fasenra doživjeli su značajna smanjenja godišnjih stopa egzacerbacija u odnosu na bolesnike koji su primali placebo.
English: Pack containing 1 single-use pre-filled syringe.
Croatian: Pakiranje sadrži 1 napunjenu štrcaljku za jednokratnu uporabu.
English: Patients that entered Trial 4 from predecessor Trials 1 and 2 with baseline blood eosinophil counts ≥300 cells/μL who were taking high-dose ICS.
Croatian: Bolesnici uključeni u Ispitivanje 4 iz prethodnih Ispitivanja 1 i 2 koji su imali početni broj eozinofila u krvi ≥ 300 stanica/μl i uzimali visoke doze IKS-a.
English: No change or no decrease in OCS
Croatian: Nema promjene ili nema smanjenja doze OKS-a Omjer izgleda (95% CI)
English: • If you are allergic to benralizumab or any of the other ingredients of this medicine (listed in section 6).
Croatian: • ako ste alergični na benralizumab ili neki drugi sastojak ovoga lijeka (naveden u dijelu 6.) Provjerite sa svojim liječnikom, medicinskom sestrom ili ljekarnikom ako mislite da bi se to moglo odnositi na Vas.
English: Histidine hydrochloride monohydrate Trehalose dihydrate Polysorbate 20
Croatian: 6.1 Popis pomoćnih tvari histidin histidinklorid hidrat trehaloza dihidrat polisorbat 20 voda za injekcije
English: Cotton ball or gauze
Croatian: Pamučna vata ili gaza Spremnik za oštre predmete
English: AstraZeneca A.E. Τηλ: +30 210 6871500
Croatian: Τηλ: +30 210 6871500
English: The green needle guard is now exposed.
Croatian: Zeleni štitnik igle sad je izložen, a služi da bi spriječio dodirivanje igle.
English: Read the instructions for use and the package leaflet before use.
Croatian: Prije uporabe pročitajte upute za uporabu i uputu o lijeku.
English: Do not use Fasenra:
Croatian: Nemojte primiti lijek Fasenra:
English: Do not re-cap the pre-filled syringe.
Croatian: Nemojte vraćati zatvarač igle na štrcaljku.
English: What Fasenra is used for
Croatian: Za što se lijek Fasenra koristi
English: Trial 1, 2 & 4
Croatian: Početna vrijednost u Ispitivanjima 1 i 2
English: (See Step 10 - Dispose of the used Fasenra Pen safely)
Croatian: • 1 neprobojan spremnik za oštre predmete (pogledajte 10. korak - Bacite upotrijebljeni Fasenra Pen na siguran način)
English: Your Fasenra pre-filled syringe
Croatian: Vaša napunjena štrcaljka s lijekom Fasenra
English: Sverige AstraZeneca AB
Croatian: AstraZeneca A.E.
English: Fasenra Pen is for single-use only.
Croatian: Pen namijenjen je isključivo za jednokratnu uporabu.
English: Fasenra 30 mg injection benralizumab SC
Croatian: Fasenra 30 mg injekcija benralizumab s.c.
English: Solution for Injection in Pre-filled Syringe Benralizumab
Croatian: Otopina za injekciju u napunjenoj brizgalici Benralizumab
English: How to store Fasenra Pen
Croatian: Kako primjenjivati Fasenra Pen
English: Label with expiration date
Croatian: Naljepnica s rokom valjanosti
English: Do not stop treatment with Fasenra unless your doctor advises you to. Interrupting or stopping the treatment with Fasenra may cause your asthma symptoms and attacks to come back.
Croatian: Privremeni ili trajni prekid liječenja lijekom Fasenra može dovesti do povratka simptoma i napadaja astme.
English: For Subcutaneous Injection Single-use Pre-filled Pen
Croatian: Za supkutanu injekciju Napunjena brizgalica za jednokratnu uporabu
English: Pre-bronchodilator FEV1 (L) Mean baseline
Croatian: FEV1 prije primjene bronhodilatatora (l) Srednja početna vrijednost
English: How Fasenra works
Croatian: Kako lijek Fasenra djeluje
English: • share or re-use your Fasenra Pen
Croatian: • dijeliti svoj Fasenra Pen s drugim osobama niti ga ponovno upotrijebiti
English: The active substance is benralizumab.
Croatian: Što lijek Fasenra sadrži Djelatna tvar je benralizumab.
English: Pharyngitis*
Croatian: FARMACEUTSKI
English: PRE-FILLED SYRINGE LABEL
Croatian: NALJEPNICA NAPUNJENE BRIZGALICE
English: Headache
Croatian: Zatvarač
English: • shake your pre-filled syringe
Croatian: • tresti napunjenu štrcaljku
English: Change from baseline for lung function, ACQ-6, and AQLQ(S)+12
Croatian: Promjena plućne funkcije te rezultata upitnika ACQ-6 i AQLQ(S)+12 u odnosu na početne vrijednosti
English: Blood eosinophil count <300 cells/μL
Croatian: Broj eozinofila u krvi < 300 stanica/μl n = 131
English: Rate ratio (95% CI) p-value
Croatian: Razlika (95% CI) p-vrijednost
English: Pre-filled syringe
Croatian: Napunjena brizgalica
English: Blood eosinophil count ≥300 cells/μL
Croatian: Broj eozinofila u krvi ≥ 300 stanica/μl n = 267
English: One pre-filled syringe contains 30 mg benralizumab in 1 mL.
Croatian: Jedna napunjena brizgalica sadrži 30 mg benralizumaba u 1 ml.
English: Grasp the syringe body (not the plunger) to remove the pre-filled syringe from its tray.
Croatian: Da biste izvadili napunjenu štrcaljku iz podloška, uhvatite je za tijelo (ne za klip).
English: AUTHORISATION
Croatian: Κύπρος
English: What are the benefits of using Fasenra
Croatian: Koje su koristi liječenja lijekom Fasenra
English: One pre-filled syringe of 1 mL solution contains 30 mg benralizumab.
Croatian: Jedna napunjena štrcaljka s 1 ml otopine sadrži 30 mg benralizumaba.
English: Rate ratio (95% CI)
Croatian: Omjer stopa (95% CI)
English: Immune system disorders
Croatian: Klasifikacija organskih sustava Nuspojava
English: Fasenra 30 mg solution for injection in pre-filled syringe benralizumab
Croatian: Fasenra 30 mg otopina za injekciju u napunjenoj brizgalici benralizumab
English: Pre-filled syringe Each pre-filled syringe contains 30 mg benralizumab* in 1 mL.
Croatian: Napunjena štrcaljka Jedna napunjena štrcaljka sadrži 30 mg benralizumaba* u 1 ml.
English: • share or re-use your pre-filled syringe
Croatian: • dijeliti svoju napunjenu štrcaljku s drugim osobama niti je ponovno upotrijebiti
English: Needle Guard
Croatian: Štitnik igle
English: Use a quick, dart-like motion to insert the needle into the pinched skin.
Croatian: Ubodite iglu u kožni nabor brzim, kratkim pokretom.
English: Tel: +46 8 553 26 000
Croatian: AstraZeneca AB Tel: +46 8 553 26 000
English: How to use Fasenra
Croatian: Kako primjenjivati lijek Fasenra
English: Fasenra 30 mg injection benralizumab Subcutaneous use
Croatian: Fasenra 30 mg injekcija benralizumab
English: Hold the Fasenra Pen with 1 hand.
Croatian: Jednom rukom uhvatite Fasenra Pen, a drugom pažljivo povucite zatvarač ravno s brizgalice.
English: Pyrexia Injection site reaction
Croatian: Opći poremećaji i reakcije na mjestu primjene pireksija reakcija na mjestu injiciranja često
English: Cap
Croatian: Učestalost
English: a 45°
Croatian: Smanjenje za ≥ 75%
English: • shake your Fasenra Pen
Croatian: • tresti Fasenra Pen
English: Improvement from baseline
Croatian: Ispitivanja egzacerbacije
English: BLISTERED PRE-FILLED SYRINGE
Croatian: NAPUNJENA ŠTRCALJKA U BLISTERU
English: Rate ratio (95% CI) Pre-bronchodilator
Croatian: Srednja vrijednost promjene FEV1 prije primjene bronhodilatatora Razlika (95% CI)
English: Green plunger
Croatian: Zeleni klip
English: Each film-coated tablet contains 300 mg of abacavir as abacavir sulphate, 150 mg lamivudine and 300 mg zidovudine
Croatian: Svaka filmom obložena tableta sadržava 300 mg abakavira (u obliku abakavirsulfata), 150 mg lamivudina i 300 mg zidovudina
English: MA (EU) number
Croatian: Broj rješenja (EU)
English: Bottle (HDPE)
Croatian: Kroz usta Bočica (HDPE)
English: Blister (PVC/PCTFE/PVCAl/Paper
Croatian: Kroz usta Blister (PVC/PCTFE/PVCAl/Papir)
English: Blister (opaque white PCTFE/PVCAl
Croatian: Kroz usta Blister (neproziran bijeli PCTFE/PVC-Al)
English: Immediate Packaging
Croatian: Primarno pakiranje Veličina pakiranja
English: (Invented) name
Croatian: Ime lijeka Jačina
English: Further information on Kymriah can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Više informacija o lijeku Kymriah možete naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Kymriah (tisagenlecleucel)
Croatian: Kymriah (tisagenlekleucel)
English: What measures are being taken to ensure the safe and effective use of Kymriah?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Kymriah?
English: Kymriah is a medicine for treating two types of blood cancer:
Croatian: Kymriah je lijek za liječenje dviju vrsta raka krvi:
English: Around 24% of patients had a complete response and 34% had at least a partial response after at least 3 months.
Croatian: Približno 24 % bolesnika u potpunosti je reagiralo, dok 34 % njih imalo najmanje djelomičnu reakciju nakon najmanje tri mjeseca.
English: Patients should be closely monitored for 10 days after treatment for side effects and are advised to stay close to a specialist hospital for at least 4 weeks after treatment.
Croatian: Bolesnike je potrebno pažljivo pratiti tijekom 10 dana nakon liječenja radi nuspojava te im savjetovati boravak u blizini specijalizirane bolnice tijekom najmanje četiri tjedna nakon liječenja.
English: Other information about Kymriah
Croatian: Ostale informacije o lijeku Kymriah
English: What is Kymriah and what is it used for?
Croatian: Što je Kymriah i za što se primjenjuje?
English: Around 66% of patients had a complete response (which means they had no signs of the cancer left) in the 3 months after treatment.
Croatian: Približno 66 % bolesnika u potpunosti je reagiralo (što znači da više nisu imali znakove raka) u tri mjeseca nakon liječenja.
English: In patients with DLBCL treated with Kymriah, the results were similar to other treatments but ongoing study data indicate that the effects last longer.
Croatian: U bolesnika s DLBCL-om koji su liječeni lijekom Kymriah, rezultati su bili slični drugim terapijama, no podatci iz ispitivanja koje se trenutačno provodi pokazuju da učinci traju dulje.
English: Serious infections occur in around 3 in 10 DLBCL patients.
Croatian: Ozbiljne su se infekcije pojavile u približno tri od 10 bolesnika s DLBCL-om.
English: Serious side effects occur in most patients.
Croatian: Ozbiljne nuspojave javljaju se u većine bolesnika.
English: These results were comparable to those from studies of patients receiving standard cancer treatments.
Croatian: Ti su rezultati biti usporedivi s rezultatima iz ispitivanja bolesnika koji su primali standardnu terapiju za rak.
English: Tocilizumab must be available in case of cytokine release syndrome.
Croatian: Tocilizumab mora biti dostupan u slučaju sindroma otpuštanja citokina.
English: Twelve months after treatment, the likelihood of survival was 70%.
Croatian: Dvanaest mjeseci nakon liječenja vjerojatnost preživljenja bila je 70 %.
English: The European Medicines Agency therefore decided that Kymriah's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove stoga je zaključila da koristi od lijeka Kymriah nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
English: Twelve months after treatment, the likelihood of survival was 40%.
Croatian: Dvanaest mjeseci nakon liječenja vjerojatnost preživljenja bila je 40 %.
English: The company that markets Kymriah must ensure that hospitals where Kymriah is given have appropriate expertise, facilities and training.
Croatian: Tvrtka koja lijek Kymriah stavlja na tržište mora osigurati da bolnice u kojima se lijek Kymriah primjenjuje imaju odgovarajuće stručnjake, prostorije i obuku.
English: This was better than results seen with the cancer medicines clofarabine, blinatumomab or a combination of clofarabine, cyclophosphamide and etoposide.
Croatian: To su rezultati bili bolji od onih opaženih s drugim lijekovima protiv raka, preciznije s klofarabinom, blinatumomabom ili s kombinacijom klofarabina, ciklofosfamida i etoposida.
English: The majority of patients who responded to Kymriah continued to have a response after 19 months.
Croatian: Većina bolesnika koji su odgovorili na lijek Kymriah nastavili su reagirati na terapiju nakon 19 mjeseci.
English: Side effects reported with Kymriah are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Kymriah pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: Why is Kymriah authorised in the EU?
Croatian: Zašto je lijek Kymriah odobren u EU-u?
English: Kymriah is a type of advanced therapy medicine called a ‘gene therapy product'.
Croatian: Kymriah je vrsta lijeka za naprednu terapiju koji se naziva „lijek za gensku terapiju”.
English: What are the risks associated with Kymriah?
Croatian: Koji su rizici povezani s lijekom Kymriah?
English: The most common serious side effects are cytokine release syndrome (a potentially life-threatening condition that can cause fever, vomiting, shortness of breath, pain and low blood pressure) and decreases in platelets (components that help the blood to clot), haemoglobin (the protein found in red blood cells that carries oxygen around the body) or white blood cells including neutrophils and lymphocytes.
Croatian: Najčešće su ozbiljne nuspojave sindrom otpuštanja citokina (stanje potencijalno opasno po život koje može prouzročiti vrućicu, povraćanje, nedostatak zraka, bol i nizak krvni tlak) te smanjeni broj trombocita (koji pomažu u zgrušavanju krvi), hemoglobina (bjelančevine koja se nalazi u crvenim krvnim zrncima te prenose kisik unutar organizma) ili bijelih krvnih zrnaca, uključujući neutrofile i limfocite.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kymriah have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Kymriah također se nalaze u sažetku opisa svojstava i u uputi o lijeku.
English: This is a type of medicine that works by delivering genes into the body.
Croatian: Riječ je o vrsti lijeka koja djeluje unosom gena u tijelo.
English: However these are manageable if the appropriate measures are in place (see below).
Croatian: Međutim, nuspojave se mogu liječiti ako se primijene prikladne mjere (vidjeti u nastavku).
English: An overview of Kymriah and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Kymriah i zašto je odobren u EU-u
English: The company must carry out several studies to obtain more information on Kymriah including its safety and effectiveness in the long term and in B-cell ALL patients under 3 years of age.
Croatian: Tvrtka mora provesti nekoliko ispitivanja kako bi pribavila dodatne informacije o lijeku Kymriah, uključujući njegovu dugoročnu sigurnost i djelotvornost te sigurnost i djelotvornost u bolesnika mlađih od tri godine s akutnom limfoblastičnom leukemijom B-stanica.
English: Serious side effects, occur in most patients, and can include cytokine release syndrome.
Croatian: Ozbiljne nuspojave javljaju se u većine bolesnika i mogu uključivati sindrom otpuštanja citokina.
English: As for all medicines, data on the use of Kymriah are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Kymriah kontinuirano se prate.
English: The company must provide educational materials for healthcare professionals and patients about possible side effects, especially cytokine release syndrome.
Croatian: Tvrtka mora zdravstvenim radnicima i bolesnicima osigurati materijale za obuku o mogućim nuspojava, posebice o sindromu otpuštanja citokina.
English: Kymriah contains the active substance tisagenlecleucel (consisting of genetically modified white blood cells).
Croatian: Kymriah sadržava djelatnu tvar tisagenlekleucel (sastoji se od genetički izmijenjenih bijelih krvnih zrnaca).
English: For more information about using Kymriah, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka Kymriah pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.
English: CAR can attach to another protein on the surface of cancer cells called CD19.
Croatian: Kimerični antigenski receptor može se vezati na drugu bjelančevinu na površini stanica raka koji se naziva CD19.
English: When Kymriah is given to the patient, the modified T cells attach to and kill the cancer cells, thereby helping to clear the cancer from the body.
Croatian: Kad se lijek Kymriah primijeni bolesniku, izmijenjene T-stanice vezuju se na stanice i raka i ubijaju ih te tako pomažu u uklanjanju raka iz organizma.
English: The main study of Kymriah in DLBCL involved 165 patients who had at least 2 previous treatments and could not have a stem cell transplant.
Croatian: U glavnom ispitivanju lijeka Kymriah sudjelovalo je 165 bolesnika s DLBCL-om koji su primili najmanje dva prethodna liječenja i nisu mogli biti podvrgnuti transplantaciji matičnih stanica.
English: A medicine called tocilizumab and emergency equipment must be available in case the patient has a potentially serious side effect called cytokine release syndrome (see risks section below).
Croatian: Lijek naziva tocilizumab kao i oprema za hitne slučajeve moraju biti na raspolaganju u slučaju da se u bolesnika pojavi potencijalno ozbiljna nuspojava koja se naziva sindrom otpuštanja citokina (vidjeti dio o rizicima u nastavku).
English: B-cell ALL patients have poor outcomes and improvements with Kymriah were better than with other medicines for this condition.
Croatian: Bolesnici s akutnom limfoblastičnom leukemijom B-stanica imaju loše ishode, no poboljšanja s lijekom Kymriah bila su bolja nego s drugim lijekovima za tu bolest.
English: Kymriah is prepared using the patient's own white blood cells which are extracted from the blood and genetically modified in the laboratory.
Croatian: Kymriah se priprema s pomoću bolesnikovih bijelih krvnih zrnaca koja se izdvajaju iz krvi i genetički izmjenjuju u laboratoriju.
English: What benefits of Kymriah have been shown in studies?
Croatian: Koje su koristi od lijeka Kymriah utvrđene u ispitivanjima?
English: Kymriah contains the patient's own T cells (a type of white blood cell) that have been modified genetically in the laboratory so that they make a protein called chimeric antigen receptor (CAR).
Croatian: Kymriah sadržava bolesnikove T-stanice (vrsta bijelih krvnih zrnaca) koje su genetički izmijenjene u laboratoriju kako bi mogle stvoriti bjelančevinu naziva kimerični antigenski receptor (engl.
English: • Diffuse large B-cell lymphoma (DLBCL) in adults whose cancer has come back or did not respond after two or more previous treatments.
Croatian: Diffuse Large B-Cell Lymphoma, DLBCL) u odraslih u kojih se rak vratio ili nije reagirao nakon dva prethodna liječenja ili više njih.
English: How does Kymriah work?
Croatian: Kako djeluje Kymriah?
English: • B-cell acute lymphoblastic leukaemia (ALL), in children and young adults up to 25 years of age whose cancer did not respond to previous treatment, has come back two or more times, or has come back after a transplant of stem cells;
Croatian: Acute Lymphoblastic Leukaemia, ALL) B-stanica u djece i mladih odraslih osoba do 25 godina u kojih rak nije reagirao na prethodno liječenje, vratio se dva ili više puta ili se vratio nakon transplantacije matičnih stanica
English: How is Kymriah used?
Croatian: Kako se Kymriah primjenjuje?
English: It is given as a single infusion (drip) into a vein and must only be given to the patient whose cells were used to make it. Before having Kymriah, the patient should have a short course of chemotherapy to clear away their white blood cells and just before the infusion, they are given paracetamol and an antihistamine medicine to reduce the risk of reactions to the infusion.
Croatian: Prije primjene lijeka Kymriah bolesnik treba proći kratki ciklus kemoterapije kako bi se uklonila bijela krvna zrnca te neposredno prije infuzije primiti paracetamol i antihistaminik kako bi se smanjio rizik od reakcija na infuziju.
English: The blood cancers that Kymriah is used to treat are rare, and Kymriah was designated an ‘orphan medicine' (a medicine used in rare diseases) for B-cell ALL on 29 April 2014 and DLBCL on 14 October
Croatian: Lijek Kymriah primjenjuje se za liječenje rijetkih vrsta raka krvi te je status lijeka za rijetku bolest za akutnu limfoblastičnu leukemiju B-stanica dobio 29. travnja 2014. te za liječenje DLBCL-a 14. listopada